Company profile
OncoC4, Inc.
Privately held: no public share price (Private clinical-stage biotech; trades only on private secondary markets, no IPO completed. Merged with AcroImmune in an all-stock deal Sept 2024 but remained private. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.nasdaqprivatemarket.com/company/oncoc4/]) · United States
Assets
(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | CTLA-4Monoclonal antibody | Non-Small Cell Lung Cancer | |
| Phase 1 | PD-1 x CTLA-4Combination | Non-Small Cell Lung Cancer |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.